SG11202004587XA - Crystalline forms of n-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide - Google Patents
Crystalline forms of n-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamideInfo
- Publication number
- SG11202004587XA SG11202004587XA SG11202004587XA SG11202004587XA SG11202004587XA SG 11202004587X A SG11202004587X A SG 11202004587XA SG 11202004587X A SG11202004587X A SG 11202004587XA SG 11202004587X A SG11202004587X A SG 11202004587XA SG 11202004587X A SG11202004587X A SG 11202004587XA
- Authority
- SG
- Singapore
- Prior art keywords
- cyclopropylmethyl
- sulfonamide
- quinoline
- piperazine
- carbonyl
- Prior art date
Links
- XAYGBKHKBBXDAK-UHFFFAOYSA-N n-[4-[4-(cyclopropylmethyl)piperazine-1-carbonyl]phenyl]quinoline-8-sulfonamide Chemical compound C=1C=C(NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)C=CC=1C(=O)N(CC1)CCN1CC1CC1 XAYGBKHKBBXDAK-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Quinoline Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762589822P | 2017-11-22 | 2017-11-22 | |
| US201862691709P | 2018-06-29 | 2018-06-29 | |
| PCT/US2018/062197 WO2019104134A1 (en) | 2017-11-22 | 2018-11-21 | Crystalline forms of n-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202004587XA true SG11202004587XA (en) | 2020-06-29 |
Family
ID=64734113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202004587XA SG11202004587XA (en) | 2017-11-22 | 2018-11-21 | Crystalline forms of n-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US11254652B2 (en) |
| EP (2) | EP4285904A3 (en) |
| JP (2) | JP7275130B2 (en) |
| CN (2) | CN111372920B (en) |
| AU (2) | AU2018373122B2 (en) |
| BR (1) | BR112020010185A2 (en) |
| CA (1) | CA3081945A1 (en) |
| DK (1) | DK3713919T3 (en) |
| ES (1) | ES2959764T3 (en) |
| FI (1) | FI3713919T3 (en) |
| HR (1) | HRP20230931T1 (en) |
| HU (1) | HUE063264T2 (en) |
| IL (2) | IL274488B2 (en) |
| LT (1) | LT3713919T (en) |
| MD (1) | MD3713919T2 (en) |
| MX (2) | MX2020005348A (en) |
| PH (1) | PH12020550644A1 (en) |
| PL (1) | PL3713919T3 (en) |
| PT (1) | PT3713919T (en) |
| RS (1) | RS64592B1 (en) |
| SG (1) | SG11202004587XA (en) |
| SI (1) | SI3713919T1 (en) |
| TW (2) | TWI808108B (en) |
| UA (1) | UA127502C2 (en) |
| WO (1) | WO2019104134A1 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2448582T3 (en) * | 2009-06-29 | 2017-09-29 | Agios Pharmaceuticals, Inc. | Quinoline-8-sulfonamide derivatives having an anticancer activity |
| KR102296703B1 (en) | 2017-03-20 | 2021-09-01 | 포르마 세라퓨틱스 인크. | Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators |
| US20230055923A1 (en) | 2018-09-19 | 2023-02-23 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| BR112021005188A2 (en) | 2018-09-19 | 2021-06-08 | Forma Therapeutics, Inc. | treating sickle cell anemia with a pyruvate kinase r activating compound |
| AU2020280045A1 (en) * | 2019-05-22 | 2021-12-23 | Agios Pharmaceuticals, Inc. | Crystalline salt forms of N-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide |
| US11878049B1 (en) | 2019-06-14 | 2024-01-23 | Agios Pharmaceuticals, Inc. | Mitapivat therapy and modulators of cytochrome P450 |
| US20230098234A1 (en) | 2020-01-28 | 2023-03-30 | Teva Pharmaceuticals International Gmbh | Solid state forms of mitapivat and process for preparation thereof |
| MX2023003431A (en) | 2020-09-25 | 2023-05-12 | Agios Pharmaceuticals Inc | Pharmaceutical formulation. |
| WO2022231627A1 (en) | 2021-04-30 | 2022-11-03 | Agios Pharmaceuticals, Inc. | Methods for titrating mitapivat for use in treating thalassemia |
| WO2023154036A1 (en) | 2022-02-08 | 2023-08-17 | Agios Pharmaceuticals, Inc. | Methods for titrating mitapivat |
| TW202308630A (en) | 2021-04-30 | 2023-03-01 | 美商阿吉歐斯製藥公司 | Methods for titrating mitapivat |
| EP4147700A1 (en) * | 2021-09-08 | 2023-03-15 | LQT Therapeutics Inc. | N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides for use in the treatment of sickle cell disease |
| WO2023091414A1 (en) | 2021-11-16 | 2023-05-25 | Agios Pharmaceuticals, Inc. | Compounds for treating mds-associated anemias and other conditions |
| WO2024084501A1 (en) | 2022-10-17 | 2024-04-25 | Mylan Laboratories Limited | Crystalline polymorphs of mitapivat and mitapivat hemisulfate |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN191496B (en) * | 1999-07-30 | 2003-12-06 | Ranbaxy Lab Ltd | |
| GB2383042A (en) * | 2001-10-18 | 2003-06-18 | Cipla Ltd | Amorphous alendronate sodium |
| PL2448582T3 (en) * | 2009-06-29 | 2017-09-29 | Agios Pharmaceuticals, Inc. | Quinoline-8-sulfonamide derivatives having an anticancer activity |
| BR112015005894B1 (en) * | 2012-09-18 | 2022-03-29 | Auspex Pharmaceuticals, Inc | Compound, pharmaceutical composition, method for treating a vmat2-mediated disorder, and extended-release pharmaceutical formulation |
| MA44392B1 (en) | 2015-06-11 | 2023-10-31 | Agios Pharmaceuticals Inc | METHODS OF USING PYRUVATE KINASE ACTIVATORS |
-
2018
- 2018-11-21 ES ES18821779T patent/ES2959764T3/en active Active
- 2018-11-21 BR BR112020010185-0A patent/BR112020010185A2/en unknown
- 2018-11-21 MD MDE20200988T patent/MD3713919T2/en unknown
- 2018-11-21 HU HUE18821779A patent/HUE063264T2/en unknown
- 2018-11-21 TW TW107141542A patent/TWI808108B/en active
- 2018-11-21 US US16/765,456 patent/US11254652B2/en active Active
- 2018-11-21 PT PT188217798T patent/PT3713919T/en unknown
- 2018-11-21 RS RS20230793A patent/RS64592B1/en unknown
- 2018-11-21 SG SG11202004587XA patent/SG11202004587XA/en unknown
- 2018-11-21 TW TW112118933A patent/TW202334115A/en unknown
- 2018-11-21 CN CN201880075099.8A patent/CN111372920B/en active Active
- 2018-11-21 PL PL18821779.8T patent/PL3713919T3/en unknown
- 2018-11-21 EP EP23186155.0A patent/EP4285904A3/en active Pending
- 2018-11-21 FI FIEP18821779.8T patent/FI3713919T3/en active
- 2018-11-21 EP EP18821779.8A patent/EP3713919B1/en active Active
- 2018-11-21 LT LTEPPCT/US2018/062197T patent/LT3713919T/en unknown
- 2018-11-21 AU AU2018373122A patent/AU2018373122B2/en active Active
- 2018-11-21 MX MX2020005348A patent/MX2020005348A/en unknown
- 2018-11-21 CN CN202311301795.5A patent/CN117551030A/en active Pending
- 2018-11-21 IL IL274488A patent/IL274488B2/en unknown
- 2018-11-21 DK DK18821779.8T patent/DK3713919T3/en active
- 2018-11-21 CA CA3081945A patent/CA3081945A1/en active Pending
- 2018-11-21 HR HRP20230931TT patent/HRP20230931T1/en unknown
- 2018-11-21 IL IL305343A patent/IL305343A/en unknown
- 2018-11-21 WO PCT/US2018/062197 patent/WO2019104134A1/en active Application Filing
- 2018-11-21 SI SI201830984T patent/SI3713919T1/en unknown
- 2018-11-21 UA UAA202003680A patent/UA127502C2/en unknown
- 2018-11-21 JP JP2020528129A patent/JP7275130B2/en active Active
-
2020
- 2020-05-15 PH PH12020550644A patent/PH12020550644A1/en unknown
- 2020-07-13 MX MX2022009998A patent/MX2022009998A/en unknown
-
2022
- 2022-01-14 US US17/575,898 patent/US20220220093A1/en active Pending
-
2023
- 2023-05-02 JP JP2023076364A patent/JP2023093762A/en active Pending
-
2024
- 2024-02-06 AU AU2024200724A patent/AU2024200724A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL274488A (en) | Crystalline forms of n-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide | |
| HK1249905A1 (en) | Heterocyclic compounds as lsd1 inhibitors | |
| IL273428B1 (en) | Heterocyclic compounds as pad inhibitors | |
| IL270869B1 (en) | Benzimidazolone derived inhibitors of bcl6 | |
| IL279949A (en) | Heterocyclic inhibitors of mct4 | |
| IL273896A (en) | Crystalline forms of 3-substituted 1,2,4-oxadiazole | |
| GB201708457D0 (en) | Inhibitors of metallo-beta-lactamases | |
| PT3636640T (en) | Crystal of heterocyclidene acetamide derivative | |
| IL268220B (en) | Co-crystals of substituted glycine compounds and uses thereof | |
| PL3532457T3 (en) | Crystalline forms of hydroxynorketamine | |
| IL272559A (en) | Method for the preparation of 4-(heptafluoro-2-propyl) anilines | |
| IL274821A (en) | Compounds as mpges-1 inhibitors | |
| ZA202003028B (en) | Novel use of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative | |
| IL270961A (en) | Crystalline form of n-butyldeoxygalactonojirimycin | |
| IL269792B (en) | Crystalline forms of (s)-afoxolaner | |
| IL288158A (en) | Crystalline salt forms of n-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide | |
| PT3131572T (en) | Use of apc analogue for wound healing | |
| GB201708451D0 (en) | Inhibitors of metallo-beta-lactamases | |
| ZA202100484B (en) | Crystal of benzoxazole derivative | |
| EP3212611A4 (en) | Crystal forms of verapamil hydrochloride | |
| EP3687987A4 (en) | Crystalline forms of lenalidomide | |
| MA50805A (en) | CRYSTALLINE FORMS OF N- (4- (4- (CYCLOPROPYLMETHYL) PIPERAZINE-1-CARBONYL) PHENYL) QUINOLEIN-8-SULFONAMIDE | |
| IL270937A (en) | Crystalline forms of seletalisib | |
| TH1501007498A (en) | Stable crystalline form of tipiracil hydrochloride. and crystallization methods for the same substances |